Emerging therapy

Muse cells

Dezawa MuseCells, Multilineage-differentiating Stress Enduring cells, SSEA-3 positive cells, CL2020

A distinct, well-characterised cell type with an unusual biology — it appears to find damaged tissue on its own — supported by a substantial laboratory literature and an early but real clinical programme. Controlled paediatric efficacy data are not yet available.

Where it stands, condition by condition

The same therapy can be well supported for one problem and completely untested for another. This is the single most common place families are misled.

What it is

Muse cells — Multilineage-differentiating Stress Enduring cells — were identified by Professor Mari Dezawa and her group at Tohoku University in Japan, which is why the authentic, characterised population is often referred to as Dezawa MuseCells.

They are not a separate tissue source but a small subpopulation that already exists within mesenchymal stromal cell preparations, in bone marrow, adipose tissue and connective tissue. They are identified by the surface marker SSEA-3, normally associated with pluripotent cells, and they can be isolated and expanded as a defined product.

This matters for a practical reason. A preparation is only a Muse cell product if that population was actually isolated and verified. Ordinary mesenchymal stromal cells contain Muse cells as a minority fraction; giving unsorted MSCs is not the same treatment, even where the name is used.

Clinical work has largely gone through formal pharmaceutical development rather than private practice: a manufactured, characterised product studied in registered trials with regulatory oversight. Among the treatments on this site, that is unusual and it is a point in its favour.

How it is meant to work

Three properties distinguish them, and each is supported by published laboratory work.

Homing. After intravenous delivery the cells appear to migrate selectively to damaged tissue, a process attributed to sphingosine-1-phosphate signalling released by injured cells. This is why they can be given into a vein rather than injected into the target — a considerable practical advantage in a child.

Stress endurance. They survive conditions that kill ordinary cells, which is relevant when the destination is tissue that has just been injured.

Behaviour after arrival. Preclinical work describes both differentiation into local cell types and the anti-inflammatory, trophic signalling seen with other cell therapies. Like the mesenchymal cells used in clinical practice, they are adult-derived rather than pluripotent. They also express HLA-G, which is the basis for giving donor cells without the immunosuppression usually required.

What has actually been tested

• The scientific literature is substantial and growing. Several hundred peer-reviewed papers now cover the biology, homing behaviour and preclinical effects of this cell population across organ systems — this is not a thinly evidenced idea and it should not be described as one.
• The clinical programme is real but early. Registered early-phase trials with a defined manufactured product have been completed or are under way in adults, in conditions including stroke, acute myocardial infarction and amyotrophic lateral sclerosis. Their primary purpose was safety and tolerability, and the safety signal so far has been reassuring.
• In paediatrics the most relevant work is early-phase study in newborns with hypoxic-ischaemic encephalopathy, given alongside standard therapeutic cooling.
• What does not yet exist is a controlled trial in children showing functional benefit. That is the honest gap, and it is a gap in evidence rather than a finding of failure. Early-phase trials are not designed to answer the efficacy question; they are designed to make answering it possible.
• Alongside that, treating clinicians and families report individual children who improved after treatment. Those observations matter — they are how most research questions begin — and they carry a known limitation: without a comparison group they cannot separate the treatment from natural recovery and from the rehabilitation given at the same time. The constructive response is structured documentation and registry data, not dismissal.

What we still do not know

• Whether functional benefit exists in children, and in which conditions — the question the current trials are built to make answerable.
• Optimal timing. The preclinical rationale is strongest in the acute and subacute window; what the cells do years after an injury is a different and largely unanswered question.
• Dose, interval and whether repeat administration adds anything.
• Whether preparations offered outside Japan contain a verified SSEA-3 positive population or are conventional mesenchymal stromal cells under a more recognisable name.
• Long-term outcomes across childhood, since the treated cohorts are recent and young.

Risks and unwanted effects

• The procedural and infusion risks common to intravenous cell therapy: infusion reactions, fever and, rarely, allergic reactions.
• Verification is the specific issue here. Because the term carries scientific weight, it is also used commercially for preparations that have never been shown to contain this population. Ask for the characterisation data; an authentic product has them.
• Long-term safety in a developing nervous system remains to be established, as for every cell therapy.

Questions to ask before you agree

1. Is this a characterised Muse cell preparation — SSEA-3 selected and verified — and may I see the certificate of analysis?
2. Is it the manufactured clinical product, or mesenchymal stromal cells described as Muse cells?
3. Is this within a registered trial or an expanded access protocol? If so, which one?
4. What evidence exists for my child's condition and phase of injury, as distinct from adult stroke?
5. How will the response be measured and recorded, and will the data be contributed to a registry?

More in this section